GlassScriptPhysician profile
Steven Andrew Dingeldein
NPI 1295759330
$8,787.81
in general payments reported to CMS, 2019-2025
29 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,226 · 2020: $389 · 2021: $892 · 2022: $1,850 · 2023: $1,376 · 2024: $1,610 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,430.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,650.67 | 2020-2025 | |
| Alcon Vision LLC | $1,607.44 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Mallinckrodt Hospital Products INC. | $1,094.12 | 2021-2025 | Acthar |
| Allergan, INC. | $604.36 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $490.62 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $470.45 | 2019-2023 | |
| Abbvie INC. | $409.81 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Oyster Point Pharma, INC. | $387.13 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $339.42 | 2022-2025 | Envista Mx60 Iol, Miebo, Envista Aspire Iol |
| Dompe US, INC. | $265.88 | 2019-2025 | Oxervate |
| Notal Vision, INC. | $262.05 | 2022-2025 | Foresee Home |
| Aerie Pharmaceuticals, INC. | $251.29 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $172.75 | 2019-2025 | |
| Astellas Pharma US INC | $158.31 | 2024 | Izervay |
| Amgen INC. | $88.29 | 2024-2025 | Tepezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $87.85 | 2025 | Vabysmo |
| Horizon Therapeutics Plc | $73.93 | 2023 | Tepezza |
| Merz North America, INC. | $54.71 | 2019 | |
| Shire North American Group INC | $51.85 | 2019 | |
| Apellis Pharmaceuticals, INC. | $43.93 | 2023 | Syfovre |
| Harrow Eye, LLC | $41.12 | 2025 | Vevye |
| Thea Pharma INC. | $36.27 | 2022-2024 | Iyuzeh |
| Coherus Oncology, INC. | $26.21 | 2023 | |
| Kala Pharmaceuticals, INC. | $24.92 | 2021 | |
| Glaukos Corporation | $24.89 | 2024 | Idose |
| Alimera Sciences, INC. | $20.08 | 2023 | Iluvien |
| Ocular Therapeutix, INC. | $19.33 | 2019 | |
| Sight Sciences, INC. | $16.08 | 2019 | |
| Tearlab Corp | $14.05 | 2024 | Scoutpro Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dingeldein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.